mutation class

Copy Number Variant

synonyms

HER2+

HER2+ve

HER2(+)

HER2 Positive

ERBB2 Amplified

ERBB2-Amplified

HER2 Amplification

Amplification of ERBB2

ERBB2/HER2 Amplification

Amplification of ERBB2/HER2

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

267 sites for NCT04784715

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +2 more drugs

targeted therapy

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

144 sites for NCT05113251

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +3 more drugs

chemotherapy, +1 more type

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

577 sites for NCT04457596

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

261 sites for NCT04873362

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

534 sites for NCT04266249

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +6 more drugs

chemotherapy, +2 more types

pembrolizumab + trastuzumab + fluoropyrimidine + platinum chemotherapy

ERBB2 Amplification, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

Locally advanced, +2 more states

First line

fluoropyrimidine, +3 more drugs

chemotherapy, +2 more types

fam-trastuzumab deruxtecan

ERBB2 Amplification, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

Locally advanced, +1 more state

Subsequent line

fam-trastuzumab deruxtecan

targeted therapy

margetuximab + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Metastatic

Subsequent line

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Early stage, +1 more state

Neoadjuvant

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Early stage

Adjuvant

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + docetaxel

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Metastatic

First line

docetaxel, +1 more drug

chemotherapy, +1 more type